


Native Vertebral Osteomyelitis and Discitis in Adults - Microbiology Summary Clinical Guideline

Reference number: CG-ANTI/2022/015



Empiric, intravenous antibiotics: clinically stable

First line	Co-amoxiclav 1.2 g 8 hourly ± If there are clinical concerns regarding the risk of MRSA, glycopeptide (vancomycin or teicoplanin), dose as per hospital guidelines , vancomycin target pre dose level 15-20 mg/l, teicoplanin target pre dose level 20-40 mg/l
Second line, if non-immediate without systemic involvement penicillin allergy	Glycopeptide (vancomycin or teicoplanin), dose as per hospital guidelines , vancomycin target pre dose level 15-20 mg/l, teicoplanin target pre dose level 20-40 mg/l and Ceftriaxone 2 g 24 hourly
Third line, if immediate rapidly evolving or non-immediate with systemic involvement penicillin allergy	Ciprofloxacin 400 mg 12 hourly and Glycopeptide (vancomycin or teicoplanin), dose as per hospital guidelines , vancomycin target pre dose level 15-20 mg/l, teicoplanin target pre dose level 20-40 mg/l

Empiric, intravenous antibiotics: clinically unstable

First line	Piperacillin tazobactam 4.5 g 8 hourly ± If there are clinical concerns regarding the risk of MRSA, glycopeptide (vancomycin or teicoplanin), dose as per hospital guidelines , vancomycin target pre dose level 15-20 mg/l, teicoplanin target pre dose level 20-40 mg/l
Second line, if non-immediate without systemic involvement penicillin allergy	Metronidazole 500 mg 8 hourly; and Glycopeptide (vancomycin or teicoplanin), dose as per hospital guidelines , vancomycin target pre dose level 15-20 mg/l, teicoplanin target pre dose level 20-40 mg/l and Ceftazidime 1 g 8 hourly
Third line, if immediate rapidly evolving or non-immediate with systemic involvement penicillin allergy	Metronidazole 500 mg 8 hourly; and Ciprofloxacin 400 mg 12 hourly and Glycopeptide (vancomycin or teicoplanin), dose as per hospital guidelines , vancomycin target pre dose level 15-20 mg/l, teicoplanin target pre dose level 20-40 mg/l

References

Bennett, J. E., Dolin, R., and Blaser, M. J. 2015. Mandell, Douglas, and Bennett's Principles and Practice of Infectious Diseases, 8th Edition. Elsevier.

Berbari, E. F., Kanj, S. S., Kowalski, T. J., Darouiche, R. O., Widmer, A. F., Schmitt, S. K., Hendershot, E. F., Holtom, P. D., Huddleston III, P. M., Petermann, G. W., and Osmon, D. R. 2015. 2015 Infectious Diseases Society of America (IDSA) Clinical Practice Guidelines for the Diagnosis and Treatment of Native Vertebral Osteomyelitis in Adults. Clinical Infectious Diseases.

Li, H., Rombach, I., Zambellas, R., Walker, A. S., McNally, M. A., Atkins, B. L., Lipsky, B. A., Hughes, H. C., Bose, D., Kumin, M., Scarborough, C., Matthews, P. C., Brent, A. J., Lomas, J., Gundle, R., Rogers, M., Taylor, A., Angus, B., Byren, I., Berendt, A. R., Warren, S., Fitzgerald, F. E., Mack, D. J. F., Hopkins, S., Folb, J., Reynolds, H. E., Moore, E., Marshall, J., Jenkins, N., Moran, C. E., Woodhouse, A. F., Stafford, S., Seaton, R. A., Vallance, C., Hemsley, C. J., Bisnauthsing, K., Sandoe, J. A. T., Aggarwal, I., Ellis, S. C., Bunn, D. J., Sutherland, R. K., Barlow, G., Cooper, C., Geue, C., McMeekin, N., Briggs, A. H., Sendi, P., Khatamzas, E., Wangrangsimakul, T., Wong, T. H. N., Barrett, L. K., Alvand, A., Old, C. F., Bostock, J., Paul, J., Cooke, G., Thwaites, G. E., Bejon, P., and Scarborough, M. 2019. Oral versus Intravenous Antibiotics for Bone and Joint Infection. The New England Journal of Medicine.

Peel, T. 2021. Vertebral osteomyelitis and discitis in adults. UpToDate. Available at: [Vertebral osteomyelitis and discitis in adults - UpToDate](#) (accessed June 2022).

Document control

Development of guidelines:	Mr Antony Bateman, Mr Jonathan Clamp, Dr Chris Durojaiye, Angelina Dyche, Kayleigh Lehal, Dr Peter Slovak
Consultation with:	Antimicrobial Pharmacist, Orthopaedic and Spinal Consultants, Infectious Diseases and OPAT Consultant, Lead Antimicrobial Pharmacist, Microbiology Consultant
Version:	2.3
Approval date:	Oct 2022
Changes from previous version:	Introduction: reworded (minor) and reformatted (minor). Differential diagnosis. Investigation: reworded (minor) and reformatted (minor). Treatment: surgical intervention and reworded (minor) and reformatted (minor). Management: reworded (minor) and reformatted (minor). References: expanded (minor).
Date uploaded:	12 Oct 2022
Next review date:	Oct 2025
Key contacts:	Dr Peter Slovak, Microbiology Consultant p.slovak@nhs.net Kayleigh Lehal, Lead Antimicrobial Pharmacist kayleigh.lehal@nhs.net Angelina Dyche, Antimicrobial Pharmacist angelinadyche@nhs.net